In addition, the presence of secondary TDP-43 pathology in diseases such as AD, chronic traumatic encephalopathy, and PD suggests broader utility in mapping disease heterogeneity and identifying patients at risk of mixed or evolving proteinopathies. This evidence concerns the gene TARDBP and Alzheimer disease.